Poliovirus Vaccine, Oral clinical trials
Its developmentBy GlaxoSmithKline, Beijing Minhai Biotechnology and Merck, step by step6 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses Poliovirus Vaccine, Oral is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2000 (1)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 6
GlaxoSmithKline (4) · Aga Khan University (2) · Centers for Disease Control and Prevention (1) · PT Bio Farma (1) · Chinese Academy of Medical Sciences (1) · Fidec Corporation (1) · Merck Sharp & Dohme LLC (1) · University of Virginia (1)
Often tested with
Tested in the same studies.
Poliovirus Vaccine, Inactivated (4) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Diphtheria-Tetanus-Pertussis Vaccine (1) · Hepatitis B Vaccines (1) · Hiberix (1) · MVAC Regimen (1) · Yellow Fever Vaccine (1) · PHiD-CV vaccine (1)
Studies
Open first, then newest update. How each study uses Poliovirus Vaccine, Oral is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity StudyCompletedPhase 4Centers for Disease Control and PreventionNCT03722004Written as bOPV
- Use of mOPV1 in Routine Immunization in Pakistan.Status unknownNot applicableAga Khan UniversityNCT04504539Written as bOPV
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01098474Written as Polio Sabin™
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & InfantsCompletedPhase 2GlaxoSmithKlineNCT01262872Written as Polio Sabin™
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00547248Written as Polio Sabin
- Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPVCompletedPhase 4PT Bio FarmaNCT03310073Written as bOPV
- Assessment of Community Transmission of Sabin Type 2 Virus in BangladeshStatus unknownPhase 3University of VirginiaNCT02477046Written as bOPV
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineCompletedPhase 3GlaxoSmithKlineNCT01457560Written as OPV
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)CompletedPhase 2Chinese Academy of Medical SciencesNCT01056705Written as Oral Poliomyelitis Vaccine
- Polio End-game Strategies - Poliovirus Type 2 Challenge StudyCompletedPhase 4Aga Khan UniversityNCT02189811Written as bOPV
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV VaccineCompletedPhase 4Fidec CorporationNCT01831050Written as Bivalent Oral Polio Vaccine (bOPV)
- Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00130832Written as Comparator: Oral Poliovirus Vaccine (OPV)
Given beside what is tested · 9 — Poliovirus Vaccine, Oral is usual care or a partner of the new treatment
- A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South AfricaCompletedPhase 2GlaxoSmithKlineNCT00263666Written as Polio Sabin
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™CompletedPhase 3GlaxoSmithKlineNCT00678301Written as GSK Biologicals' Polio Sabin™
- Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedPhase 3GlaxoSmithKlineNCT01175083Written as Polio Sabin
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00344318Written as Polio Sabin.
- Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)CompletedPhase 3Merck Sharp & Dohme LLCNCT02062385Written as OPV
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedPhase 3GlaxoSmithKlineNCT00829010Written as Local OPV
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI RegimenCompletedPhase 2GlaxoSmithKlineNCT00436007Written as Polio Sabin™
- Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African InfantsCompletedPhase 2GlaxoSmithKlineNCT01231503Written as OPV
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV VaccineStatus unknownPhase 4University of ChileNCT01841671Written as bOPV
As the comparator · 3 — what is tested is compared with Poliovirus Vaccine, Oral
- Sex-Differential Health Interventions In Low-Birth-Weight InfantsCompletedNot applicableBandim Health ProjectNCT00625482Written as OPV
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ VaccineCompletedPhase 3GlaxoSmithKlineNCT01021293Written as Oral Poliovirus vaccine
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in ThailandCompletedPhase 4Universiteit AntwerpenNCT02408926Written as OPV